Effect of a leukotriene receptor antagonist on the prevention of recurrent asthma attacks after an emergency room visit

Kazuto Matsunaga, Takeshi Nishimoto, Tsunahiko Hirano, Masanori Nakanishi, Toshiyuki Yamagata, Yoshiaki Minakata, Mayu Kuroda, Takeshi Ikeda, Hirotaka Nakanishi, Masakazu Ichinose

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Background: The efficacy of montelukast, a specific cysteinyl leukotriene receptor antagonist, in preventing recurrent asthma attacks was evaluated for post-emergency management of acute asthma exacerbation. Methods: Twenty-two patients with a history of chronic asthma whose symptoms were responsive to an inhaled β-adrenergic receptor agonist in an emergency room setting, were randomized into two groups, those with and those without montelukast (n = 11 for each group). Patients in the montelukast group received an oral dose of 10 mg montelukast before leaving the emergency room following rescue treatment with an inhaled β-adrenergic receptor agonist. Patients in both groups were instructed to use an inhaled β-adrenergic receptor agonist for shortness of breath or dyspnea in post-emergency management. Additional β-adrenergic receptor agonist use, subjective asthma symptoms, sleep impairment, additional emergency visits and/or hospitalization were monitored for 24 hours following the emergency room visit. Results: In the montelukast group, the need for a rescue β-adrenergic receptor agonist was significantly decreased; 54.5% of patients in the montelukast group required use of β-adrenergic receptor agonist compared with 100% in the non-montelukast group (P < 0.05). The average number of uses of a β-adrenergic receptor agonist was 2.67 ± 3.58 times/ 24 h in the montelukast group compared with 11.95 ± 3.60 times/24 h in the non-montelukast group (P < 0.01). The average subjective asthma symptom scores were significantly decreased in the montelukast group, whereas no score change occurred in the non-montelukast group. The sleep impairment score was significantly lower in the montelukast group compared with that in the non-montelukast group (P < 0.05). No patients in either group had an emergency visit or hospitalization during this period. Conclusions: The results demonstrate that montelukast can prevent recurrent asthma exacerbations in the home environment.

Original languageEnglish
Pages (from-to)341-347
Number of pages7
JournalAllergology International
Volume53
Issue number4
DOIs
Publication statusPublished - 2004 Dec

Keywords

  • Asthma exacerbation
  • Leukotriene receptor antagonist
  • Montelukast
  • β-adrenergic receptor agonist

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Effect of a leukotriene receptor antagonist on the prevention of recurrent asthma attacks after an emergency room visit'. Together they form a unique fingerprint.

Cite this